Cargando…

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-convertin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bönner, G, Bakris, G L, Sica, D, Weber, M A, White, W B, Perez, A, Cao, C, Handley, A, Kupfer, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715765/ https://www.ncbi.nlm.nih.gov/pubmed/23514842 http://dx.doi.org/10.1038/jhh.2013.6

Ejemplares similares

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
por: Cushman, William C., et al.
Publicado: (2018)

Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
por: White, William B., et al.
Publicado: (2016)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
por: Wang, Ji‐Guang, et al.
Publicado: (2021)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats
por: Kosacka, Joanna, et al.
Publicado: (2022)

Marketing research on the angiotensin-converting enzyme inhibitors antihypertensive medicines
por: BOBOIA, ANAMARIA, et al.
Publicado: (2017)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Ku, Elaine, et al.
Publicado: (2018)

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
por: Weber, Michael A, et al.
Publicado: (2018)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
por: Sarangarajan, Rangaprasad, et al.
Publicado: (2020)

Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
por: Nade, V. S., et al.
Publicado: (2015)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2020)

Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease
por: Huh, Terry, et al.
Publicado: (2020)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
por: Mao, Yeqing, et al.
Publicado: (2016)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients
por: Mekary, Wissam, et al.
Publicado: (2023)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_utuflm29enan2q4dlq6lr7vnva